Skip Ribbon Commands
Skip to main content



BronchiectasisPhase II Trial on using new drug for targeted Bronchiectasis therapy.
Kidney Disease (Membranous Nephropathy)The purpose of the study is to find out if the drug called “LNP023” is safe and has beneficial effects in people who have membranous nephropathy (MN) compared with rituximab. MN is a disease of the kidney that causes an increase in the amount of protein eliminated in the urine. The main objective of this research is to see whether taking LNP023 or rituximab for 6 months results in lower urine protein levels and to compare these two treatments in patients with MN.
Breast Cancer​HER2-, Hormone Receptor +, Advanced Breast Ca